Reassessing antiviral treatment criteria for chronic hepatitis B
- PMID: 37246445
- DOI: 10.1097/HEP.0000000000000496
Reassessing antiviral treatment criteria for chronic hepatitis B
Comment on
-
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase.Hepatology. 2023 Nov 1;78(5):1558-1568. doi: 10.1097/HEP.0000000000000459. Epub 2023 May 16. Hepatology. 2023. PMID: 37184202
References
-
- World Health Organisation. Factsheet on Hepatitis B. Accessed May 1, 2023. https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
-
- Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67:1560–1599.
-
- Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci. 2015;60:1457–1464.
-
- Hall SAL, Vogrin S, Wawryk O, Burns GS, Visvanathan K, Sundararajan V, et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis. Gut. 2022;71:1629–1641.
-
- Jeng WJ, Lok AS. Should treatment indications for chronic hepatitis B be expanded? Clin Gastroenterol Hepatol. 2021;19:2006–2014.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
